IceCure Medical's ProSense Shows Efficacy in Endometriosis Study
Ticker: ICCM · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1584371
Sentiment: bullish
Topics: medical-device, study-results, womens-health
TL;DR
IceCure's ProSense system significantly cuts endometriosis pain, study shows.
AI Summary
On September 4, 2025, IceCure Medical Ltd. announced positive results from a study on its ProSense system for treating abdominal wall endometriosis. The study demonstrated that the ProSense system substantially reduced pain and showed high procedural efficacy in patients.
Why It Matters
This announcement highlights the potential of IceCure's technology to address a significant unmet need in women's health, potentially expanding its market reach.
Risk Assessment
Risk Level: medium — The filing reports on a study's positive results, which is good, but doesn't include financial data or significant corporate actions that would indicate a higher risk.
Key Players & Entities
- IceCure Medical Ltd. (company) — The company issuing the report and announcing study results.
- ProSense® (product) — The medical system used in the study.
- September 4, 2025 (date) — The date of the press release and filing.
FAQ
What specific metric demonstrated the 'substantial reduction' in pain for abdominal wall endometriosis?
The filing refers to a press release (Exhibit 99.1) for details, but the 6-K itself does not specify the exact pain reduction metric or percentage.
What is the 'high procedural efficacy' mentioned in the press release?
The press release, furnished as Exhibit 99.1, is cited as the source for this information, but the 6-K document does not provide the specific definition or measure of procedural efficacy.
When was the press release titled 'IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy' issued?
The press release was issued on September 4, 2025.
What is the primary purpose of this Form 6-K filing for IceCure Medical Ltd.?
The primary purpose is to report a press release issued by the Company regarding the efficacy of its ProSense system in treating abdominal wall endometriosis.
Does this filing include financial information or updates on the company's financial performance?
No, this Form 6-K filing primarily contains a press release about a medical study and does not include financial statements or performance updates.
Filing Stats: 297 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2025-09-04 08:45:28
Filing Documents
- ea0255986-6k_icecure.htm (6-K) — 11KB
- ea025598601ex99-1_icecure.htm (EX-99.1) — 15KB
- 0001213900-25-084285.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: September 4, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2